<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638766</url>
  </required_header>
  <id_info>
    <org_study_id>REGISTRI (GEIS 40)</org_study_id>
    <nct_id>NCT02638766</nct_id>
  </id_info>
  <brief_title>Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST</brief_title>
  <acronym>REGISTRI</acronym>
  <official_title>Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable&#xD;
      KIT/PDGFR wild type GIST in the first line setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SDH complex is involved in mitochondrial Krebs cycle and defects in the succinate&#xD;
      dehydrogenase (SDH) complex have identified, as previously mentioned, in KIT/PDGFR WT. This&#xD;
      complex, SDH, has 4 subunits (A-D) and SDH-A or SDH-B are involved in oxidization succinate&#xD;
      to fumarate. Therefore, loss of function owing to mutational inactivation leads to the&#xD;
      cytoplasmic accumulation of succinate which downregulates prolyl hydroxylase. This enzyme has&#xD;
      a negative regulator role of hypoxia-inducible factor 1α (HIF1α) since promotes its&#xD;
      proteasomal degradation. Increased levels of HIF1α can enter the nucleus and activate the&#xD;
      transcription of vascular endothelial growth factor (VEGFR)24. In fact, the VEGFR expression&#xD;
      is higher in KIT/PDGFR WT than in KIT mutant GISTs25.&#xD;
&#xD;
      Approximately 50% of KIT/PDGFR WT show high expression of insulin-like growth factor 1&#xD;
      receptor (IGFR1). This expression may correlate also with the loss of SDH due to IGF&#xD;
      autocrine loop26. IGFR signals through both MAPK and PI3K-AKT pathways. As previously&#xD;
      mentioned, Regorafenib is able to block MAPK signaling pathway at different levels.&#xD;
      Interestingly, early interstitial Cajal cell (ICC) progenitors have a phenotype of&#xD;
      KITlowCD44+CD34+IGFR+ while committed lineage of progenitors have KIThighCD44+CD34-IGFR-.&#xD;
      Unlike mature or more committed lineage of ICCs, the KITlowCD44+CD34+IGFR+ display resistance&#xD;
      to Imatinib in spite of kit signaling pathway activation. Thus Regorafenib could gain&#xD;
      advantage over Imatinib for treating KIT/PDGFR WT27,28.&#xD;
&#xD;
      On the other hand, other subsets within of KIT/PDGFR WT as B-RAF mutants or NF1-associated&#xD;
      GIST could also be sensitive to Regorafenib. In this later subset, protein expression of&#xD;
      phospho-MAPK was seen in 92% of cases in a series of 25 patients29.&#xD;
&#xD;
      Theoretically Regorafenib could also act blocking STAT3, which is activated by RET&#xD;
      proto-oncogen, through RET inhibition. STAT3 is implicated as downstream pathway signal in&#xD;
      GIST30.&#xD;
&#xD;
      Taken together, the previous data suggests Regorafenib could play a relevant role as upfront&#xD;
      treatment of metastatic or unresectable locally advanced KIT/PDGFR WT GIST.&#xD;
&#xD;
      Subjects will receive 160mg (4 tablets) of regorafenib once a day every day for 3 weeks of&#xD;
      every 4 week cycle (i.e., 3 weeks on, 1 week off). The study drug will be orally&#xD;
      administered.&#xD;
&#xD;
      Doses of study drug may be delayed or reduced in case of clinically significant hematologic&#xD;
      and other toxicities. Toxicities will be graded using the CTCAE v 4.03. The modifications of&#xD;
      regorafenib are detailed in the protocol for general event, Hand Foot Skin Reaction,&#xD;
      Hypertension and drug-related liver function test abnormalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>every 8 weeks during 36 months</time_frame>
    <description>the sum of complete responses (CR) + partial responses (PR) + stable disease (SD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>every 8 weeks during 36 months</time_frame>
    <description>Number of months without progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 8 weeks during 36 months</time_frame>
    <description>Number of months alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses determined by CHOI</measure>
    <time_frame>every 8 weeks during 36 months</time_frame>
    <description>Measure tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with translational research</measure>
    <time_frame>After 36 months of recruitment</time_frame>
    <description>Relation between the clinical data obtained and the data obtained from translational research</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events following CTCAE v4.03)</measure>
    <time_frame>Every 28 days until 30 days after last dose</time_frame>
    <description>Evaluation of adverse events following CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early metabolic response by PET scan</measure>
    <time_frame>After 1 month of starting treatment</time_frame>
    <description>Evaluation of metabolic response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by EORCT QLQ C30 questionnaire</measure>
    <time_frame>Day 1 of each cycle. Pre-treatment administration</time_frame>
    <description>EORCT QLQ C30 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by EQ-ED-5L questionnaire</measure>
    <time_frame>Day 1 of each cycle. Pre-treatment administration</time_frame>
    <description>EQ-ED-5L questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Unique arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days</description>
    <arm_group_label>Unique arm</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must provide written informed consent prior to performance of study-specific&#xD;
             procedures or assessments and must be willing to comply with treatment and follow-up.&#xD;
&#xD;
             Informed Consent must be obtained prior to start of the screening process. Procedures&#xD;
             conducted as part of the patient´s routine clinical management (e.g. blood count,&#xD;
             imaging tests, etc.) and obtained prior to signature of informed consent may be used&#xD;
             for screening or baseline purposes as long as these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          2. Male or female subjects ≥18 years of age&#xD;
&#xD;
          3. Histologically confirmed GIST KIT/PDGFR wild-type, unresectable or metastatic GIST&#xD;
             (confirmed by central laboratory). Paraffin-embedded tumor block must be provided by&#xD;
             all subjects during screening period.&#xD;
&#xD;
          4. Screening of mutations done in exon 11, 9, 13 and 17 in KIT gene and in 12 and 18&#xD;
             exons of PDGFR gene&#xD;
&#xD;
          5. Subjects must have at least one measurable lesion according to RECIST v1.1 criteria. A&#xD;
             lesion in a previously irradiated area is eligible to be considered as measurable&#xD;
             disease as long as there is objective evidence of progression of the lesion prior to&#xD;
             study enrolment.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          7. Adequate bone marrow, liver, and renal function as assessed by the following&#xD;
             laboratory requirements conducted within 7 days of starting study treatment:&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5 x the upper normal limit (UNL). Documented Gilbert Syndrome&#xD;
                  is allowed if total bilirubin is mildly elevated (≤6mg/dl).&#xD;
&#xD;
               -  Alanine Aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x UNL&#xD;
                  (≤5xUNL for subjects with liver involvement of GIST)&#xD;
&#xD;
               -  Lipase ≤1.5 x UNL&#xD;
&#xD;
               -  Serum Creatinine ≤ 1.5 x UNL&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) ≥ 30ml/mn/1.73 m2 according to the Modified Diet&#xD;
                  in Renal Disease (MDRD) abbreviated formula.&#xD;
&#xD;
               -  International Normalized Ratio (INR) ≤1.5xUNL and partial thromboplastin time&#xD;
                  (PTT) or activated partial thromboplastin time (aPTT) ≤1.5xUNL. Subjects who are&#xD;
                  being treated with an anti-coagulant, such as warfarin or heparin, will be&#xD;
                  allowed to participate provided that no prior evidence of an underlying&#xD;
                  abnormality in these parameters exists. Close monitoring of at least weekly&#xD;
                  evaluations will be performed until INR and PTT are stable based on a pre-dose&#xD;
                  measurement as defined by the local standards of care.&#xD;
&#xD;
               -  Platelet count ≥100000mm3, hemoglobin (Hb) ≥ 9.0 g/dl, absolute neutrophil count&#xD;
                  (ANC) ≥1500/mm3. Blood transfusions to meet the inclusion criteria will not be&#xD;
                  allowed.&#xD;
&#xD;
               -  Alkaline phosphatase limit ≤ 2.5 x UNL (≤ 5x UNL for subjects with disease&#xD;
                  involving the liver)&#xD;
&#xD;
          8. Women of childbearing potential and men must agree to use adequate contraception from&#xD;
             the moment of signing the Informed Consent Form until at least 3 months after the last&#xD;
             study drug administration. The investigator or a designated associate is requested to&#xD;
             advise the subject on how to achieve an adequate birth control. Adequate contraception&#xD;
             is defined in the study as any medically recommended method (or combination of&#xD;
             methods) as per standard of care.&#xD;
&#xD;
          9. Women of childbearing potential must have a blood or urine pregnancy test performed a&#xD;
             maximum of 7 days before start of study treatment, and a negative result must be&#xD;
             documented before start of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior systemic treatment for GIST BESIDES IMATINIB. Patients that have relapsed after&#xD;
             receiving imatinib during adjuvant setting and patients who are on treatment or have&#xD;
             been treated with Imatinib as first line of advanced KIT/PDGFRa wild type GIST are&#xD;
             eligible.&#xD;
&#xD;
          2. Cancer other than GIST within 5 years prior to randomization EXCEPT for curatively&#xD;
             treated cervical cancer in situ, non-melanoma skin cancer, and superficial bladder&#xD;
             tumors (Ta (Non Invasive tumor), and Tis (Carcinoma In situ)).&#xD;
&#xD;
          3. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             before the start of study medication.&#xD;
&#xD;
          4. Congestive Heart Failure New York Heart Association (NYHA) ≥ class 2.&#xD;
&#xD;
          5. Unstable angina (angina symptoms at rest, new-onset angina, ie, within the lasts 3&#xD;
             months prior to entering study) or myocardial infarction (MI) within the past 6 months&#xD;
             before the start of study medication.&#xD;
&#xD;
          6. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are&#xD;
             permitted).&#xD;
&#xD;
          7. Uncontrolled hypertension (Systolic blood pressure &gt; 140 mmHg or diastolic pressure &gt;&#xD;
             90mmHg despite optimal medical management).&#xD;
&#xD;
          8. Subjects with pheochromocytoma.&#xD;
&#xD;
          9. Arterial thrombotic or embolic events such as cerebrovascular accident (including&#xD;
             transient ischemic attacks), or pulmonary embolism within 6 months from start of study&#xD;
             treatment.&#xD;
&#xD;
         10. Venous thrombotic events such as deep vein thrombosis within the 3 months before the&#xD;
             start of study treatment.&#xD;
&#xD;
         11. Ongoing infection &gt; grade 2 National Cancer Institute- Common Terminology Criteria for&#xD;
             Adverse Events (NCI-CTCAE) version 4.03&#xD;
&#xD;
         12. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         13. Subjects with seizure disorder requiring medication&#xD;
&#xD;
         14. Symptomatic metastasis in brain or meningeal tumors.&#xD;
&#xD;
         15. History of organ allograft.&#xD;
&#xD;
         16. Subjects with evidence or history of bleeding diathesis. Any hemorrhage or bleeding&#xD;
             event ≥ NCI-CTCAE version 4.03 grade 3 or higher within 4 weeks prior to start of&#xD;
             study treatment.&#xD;
&#xD;
         17. Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         18. Renal failure requiring hemo- or peritoneal dialysis.&#xD;
&#xD;
         19. Dehydration NCI-CTCAE version 4.03 grade ≥ 1&#xD;
&#xD;
         20. Substance abuse or medical, psychological, or social conditions that may interfere&#xD;
             with the subject´s participation in the study or evaluation of the study results.&#xD;
&#xD;
         21. Known hypersensitivity to the study drug, study drug class, or excipients in the&#xD;
             formulation.&#xD;
&#xD;
         22. Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the subject and his/her compliance in the study&#xD;
&#xD;
         23. Interstitial lung disease with ongoing signs and symptoms at the time of screening.&#xD;
&#xD;
         24. Subjects unable to swallow oral medication&#xD;
&#xD;
         25. Persistent proteinuria of NCI-CTCAE version 4.03 grade 3 or higher (&gt;3.5g/24hrs),&#xD;
             measured by urine protein creatinine ratio on a random urine sample)&#xD;
&#xD;
         26. Any malabsorption condition.&#xD;
&#xD;
         27. Left Ventricular Ejection Fraction (LVEF) &lt; 50% or below the LLN for the institution&#xD;
             (whichever is higher).&#xD;
&#xD;
         28. Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version&#xD;
             4.03 grade 2 dyspnea)&#xD;
&#xD;
        NOTE: It is not necessary to demonstrate disease progression or imatinib intolerance to&#xD;
        offer the study entrance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martín-Broto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GEIS (GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virginia Martínez-Marín, MD</last_name>
    <role>Study Director</role>
    <affiliation>GEIS (GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mamen De Juan, RGN</last_name>
    <phone>0034912866807</phone>
    <email>mamen.crc@grupogeis.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Fernandez-Pinto, MSc</last_name>
    <phone>0034912866807</phone>
    <email>melissa.crc@grupogeis.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine Italiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Gautier</last_name>
      <email>julien.gautier@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Ives Blay, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Axel Le Cesne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Dei Tumori di Milano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo G. Casalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Milano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Armando Santoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Vincenzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - IRCSS</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Grignani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natalia Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A. Lopez Pousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rosa Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Virginia Martinez Marín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Martín-broto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Vicente Baz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andres Poveda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Martinez Trufero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>unresectable</keyword>
  <keyword>KIT/PDGFR wild type GIST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

